In Indonesia, as in many other nations, cancer stands as a major public health concern, with the most prevalent types including breast, cervical, lung, colorectal, and liver cancer. The country encounters distinct obstacles in cancer care, such as limited access to programs for early detection, a deficit in healthcare facilities and oncology specialists, and the inaccessible treatment costs for many. Furthermore, a general lack of awareness regarding cancer prevention and the importance of early detection contribute to diagnoses at advanced stages and diminished survival rates. Consequently, the advancement of oncology in Indonesia is geared towards enhancing early detection and screening initiatives, raising public awareness about cancer, and improving the healthcare system along with making treatments more accessible and affordable. Additionally, there is an increasing trend towards combining conventional and novel cancer treatment methods to offer comprehensive care to patients.

The field of clinico-genomic research holds considerable promise for oncology in Indonesia by pinpointing genetic and molecular markers unique to the Indonesian populace that influence cancer susceptibility, progression, and response to treatment. Our studies aim to facilitate personalized treatment approaches, which could significantly enhance treatment efficacy and potentially lower death rates.